Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein Q1 includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3—X1— wherein X1 includes a direct bond and O and Q3 includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R2 and R3 is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q2 includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.

Abstract: The invention concerns cycloalkane derivatives of the formula I ##STR1## wherein Ar.sup.1 is phenyl, naphthyl or a 10-membered bicyclic heterocyclic moiety which may optionally bear up to four substituents;A.sup.1 is a direct link to X.sup.1 or is (1-3C)alkylene;X.sup.1 is oxy, thio, sulphinyl or sulphonyl;Ar.sup.2 is phenylene, pyridylene, pyrimidinylene, thiophenediyl, furandiyl, thiazolediyl or oxazolediyl which may optionally bear one or two substituents;p is 1 to 4;q is 0 to 2;R.sup.1 is hydrogen, (1-4C)alkyl, (2-4C)alkenyl or (3-4C)alkynyl;R.sup.2 is hydrogen, hydroxy, (1-4C)alkyl, (1-4C)alkoxy, (2-4C)alkenyloxy or (3-4C)alkynyloxy;or the OR.sup.1 and R.sup.2 groups together form a (1-4C)alkylenedioxy, oxo, thioxo, imino, hydroxyimino or (1-4C)alkoxyimino group;r is 0 to 3; andR.sup.3 is halogeno, trifluoromethyl or (1-4C)alkyl;or a pharmaceutically-acceptable salt thereof;processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.